Previous close | 34.90 |
Open | 34.86 |
Bid | 33.89 x 100 |
Ask | 34.01 x 200 |
Day's range | 33.90 - 35.58 |
52-week range | 13.57 - 53.08 |
Volume | |
Avg. volume | 766,688 |
Market cap | 2.322B |
Beta (5Y monthly) | 1.89 |
PE ratio (TTM) | N/A |
EPS (TTM) | -6.62 |
Earnings date | 03 May 2024 - 07 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 70.83 |
Novartis (NVS) enters into a license deal with Arvinas, Inc. (ARVN) for the worldwide development and commercialization of cancer candidate ARV-766. Shares of ARVN rise on the news.
Biotech stocks heated up Thursday as Novartis scooped up a licensing pact with Arvinas and Janux was said to be exploring strategic options.
Swiss drugmaker Novartis AG has entered into a licensing deal worth up to $1.01 billion with Arvinas to gain access to the U.S. biotech firm's experimental prostate cancer drug, Arvinas said on Thursday. Shares of Connecticut-based Arvinas rose more than 6% to $39 in premarket trade. The pact adds to Novartis' pursuit of cancer treatments after it launched a tender offer on Thursday to acquire German cancer drugmaker MorphoSys for an aggregate 2.7 billion euros ($2.9 billion).